Literature DB >> 33078320

Thrombus-First Surgery for Hepatocellular Carcinoma with Bile Duct Tumor Thrombus.

Juxian Sun1, Jiayi Wu2, Jie Shi1, Chang Liu1, Yonggang Wei3, Jianyin Zhou4, Zhibo Zhang5, Maolin Yan6, Shuqun Cheng7.   

Abstract

OBJECTIVE: The optimal surgical method of patients with hepatocellular carcinoma (HCC) and bile duct tumor thrombus (BDTT) is still controversial. This study aims to investigate the impact of different surgical methods on BDTT patients.
METHODS: A multicenter retrospective study was carried out on HCC patients with BDTT who underwent surgery. The survival outcomes of different operation methods were studied.
RESULTS: A total of 120 HCC patients with BDTT from 5 different clinical centers were included. The median disease-free survival (DFS) of the bile duct resection (BDR) group was significantly better than that of the non-BDR group (24.6 months vs. 18.9 months, p = 0.034), but the overall survival (OS) was similar between the two groups (33.6 months vs. 32.3 months, p = 0.193). When we divided the non-BDR group into two groups according to the operation sequence of the hepatic tumor and BDTT, we found that the OS of the thrombus-first group was significantly longer than that of the tumor-first group (42.7 months vs. 23.6 months, p = 0.016). When compared with the BDR group, the thrombus-first group showed similar OS (42.7 months vs. 33.6 months, p = 0.653) and DFS (24.7 months vs. 24.6 months, p = 0.150), which may be the reason the OS rate of the BDR group was similar to that of the non-BDR group.
CONCLUSIONS: A thrombus-first technique could be considered for HCC patients with extrahepatic BDTT, especially for those patients in which the tumor thrombus did not invade the bile duct.
© 2020. The Society for Surgery of the Alimentary Tract.

Entities:  

Keywords:  Bile duct tumor thrombus; Hepatocellular carcinoma; Obstructive jaundice; Surgery

Mesh:

Year:  2020        PMID: 33078320     DOI: 10.1007/s11605-020-04813-1

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  1 in total

1.  Usefulness of resection for hepatocellular carcinoma with macroscopic bile duct tumor thrombus.

Authors:  Atsushi Oba; Shinichiro Takahashi; Yuichiro Kato; Naoto Gotohda; Takahiro Kinoshita; Hidehito Shibasaki; Masafumi Ikeda; Masaru Konishi
Journal:  Anticancer Res       Date:  2014-08       Impact factor: 2.480

  1 in total
  2 in total

1.  Efficacy and Safety of Transarterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma Associated with Bile Duct Tumor Thrombus: A Real-World Retrospective Cohort Study.

Authors:  Jin-Kai Feng; Ju-Xian Sun; Zong-Han Liu; Jing-Wen Gu; Zhen-Hua Chen; Chang Liu; Wei-Xing Guo; Jie Shi; Shu-Qun Cheng
Journal:  Cancer Manag Res       Date:  2021-04-28       Impact factor: 3.989

2.  Prognostic Comparison Between Liver Resection and Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Patients With Bile Duct Tumor Thrombus: A Propensity-Score Matching Analysis.

Authors:  Zong-Han Liu; Ju-Xian Sun; Jin-Kai Feng; Shi-Ye Yang; Zhen-Hua Chen; Chang Liu; Zong-Tao Chai; Fei-Fei Mao; Wei-Xing Guo; Jie Shi; Shu-Qun Cheng
Journal:  Front Oncol       Date:  2022-03-15       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.